Literature DB >> 35362794

First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner.

Adrienne H Brouwers1, Joyce van Sluis2, Johannes H van Snick2, Carolina P Schröder2,3, Inge O Baas4, Ronald Boellaard2,5, Andor W J M Glaudemans2, Ronald J H Borra2, Adriaan A Lammertsma2, Rudi A J O Dierckx2, Charalampos Tsoumpas2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35362794      PMCID: PMC9308603          DOI: 10.1007/s00259-022-05777-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


× No keyword cloud information.
Long axial field-of-view (LAFOV) PET/CT scanners have been introduced recently [1, 2], which offer numerous advantages [3]. One important advantage of using LAFOV PET/CT for imaging 89Zr-labelled monoclonal antibodies (mAbs), i.e., immunoPET, is the substantial increase in sensitivity compared with standard axial field-of-view (SAFOV) PET/CT systems, which may lead to a remarkable image quality improvement. This first study showcases such improvement for immunoPET with Biograph Vision Quadra™ (VQ) LAFOV PET/CT (Siemens Healthineers, Knoxville, TN, USA). Two patients suffering from metastatic HER2-positive breast cancer were administered with 37 MBq [89Zr]trastuzumab in order to assist clinical decision-making [4, 5]. Patients were scanned 4 days postinjection with a Biograph™ mCT PET/CT (patient A) or a Biograph Vision™ PET/CT (patient B) (Siemens Healthineers, Knoxville, TN, USA), according to local standard operating procedures with overall scan durations of 45 min and 32 min, for, respectively, mCT and Vision. Following the clinical scans, patients were scanned with VQ. For VQ, we choose to apply a long scan duration of 30 min (patient A) and 32 min (patient B) to improve image quality rather than shortening the overall scan duration, as compared to Vision. For SAFOV systems, the acquisition and reconstruction parameters complied with EARL1, whilst for LAFOV, we also applied clinically (CLIN) recommended settings (Table 1) [6, 7].
Table 1

Acquisition and reconstruction parameters for the different systems

PET/CT systemAcquisition methodReconstruction protocol nameReconstruction settings
Biograph mCTStep and shoot: 5 min per bed position (bp), 9 bpEARL1OSEM, 3i21s, size 256 × 256 × 488, voxel size 3.2 × 3.2 × 2.0 mm3, 6.5 mm FWHM Gaussian filter
Biograph VisionFlow: continuous bed motion, 8 min per body pass, 4 passesEARL1OSEM, 4i5s, size 220 × 220 × 706, voxel size 3.3 × 3.3 × 1.5 mm3, 7 mm FWHM Gaussian filter
Biograph Vision QuadraSingle bpEARL1OSEM, 4i5s, size 220 × 220 × 708, voxel size 3.3 × 3.3 × 1.5 mm3, 7 mm FWHM Gaussian filter
Single bpCLINOSEM, 4i5s, size 440 × 440 × 708, voxel size 1.6 × 1.6 × 1.5 mm3, no filtering

EARL European Association of Nuclear Medicine Research Ltd., OSEM 3D ordered subset expectation maximization with time-of-flight and point spread function, i iterations, s subsets, FWHM full width at half maximum

Acquisition and reconstruction parameters for the different systems EARL European Association of Nuclear Medicine Research Ltd., OSEM 3D ordered subset expectation maximization with time-of-flight and point spread function, i iterations, s subsets, FWHM full width at half maximum PET/CT images of patient A are shown in the top two rows (a-h), for patient B in the bottom rows (i-p). The same intensity scale, SUV range 0–10, applies for all images, except the fused images (e, m). Additional reconstructions of the Vision Quadra data were obtained, mimicking 3-min (d, h, l, p) and 10-min (c, g, k, o) acquisitions, illustrating more pragmatic scan durations. As can be appreciated from these first human immunoPET images on a LAFOV system, the image quality improvement (f) is most spectacular when compared with the mCT (a). For example, in patient A, an additional small bone lesion was visualized with VQ in the pelvic area (f), which was not visible with the SAFOV system (a). Even when compared to the Vision (i), the VQ image (n) shows improved quality without applying any filter after reconstruction. Moreover, this image quality was improved even in the 10 min image compared with the 30–45 min acquisition needed for SAFOV systems. Thus, this image shows that the large axial FOV system provides substantial improvement in image quality when applying currently preferred overall scan durations on SAFOV systems (45 min for mCT, 32 min for Vision). Additionally, with the new LAFOV system, there is room for further reduction of the overall scan duration with still very acceptable image quality, even for 89Zr-labelled mAb PET/CT studies.
  7 in total

1.  First Human Imaging Studies with the EXPLORER Total-Body PET Scanner.

Authors:  Ramsey D Badawi; Hongcheng Shi; Pengcheng Hu; Shuguang Chen; Tianyi Xu; Patricia M Price; Yu Ding; Benjamin A Spencer; Lorenzo Nardo; Weiping Liu; Jun Bao; Terry Jones; Hongdi Li; Simon R Cherry
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

2.  Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.

Authors:  E C Dijkers; T H Oude Munnink; J G Kosterink; A H Brouwers; P L Jager; J R de Jong; G A van Dongen; C P Schröder; M N Lub-de Hooge; E G de Vries
Journal:  Clin Pharmacol Ther       Date:  2010-03-31       Impact factor: 6.875

3.  Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard.

Authors:  George A Prenosil; Hasan Sari; Markus Fürstner; Ali Afshar-Oromieh; Kuangyu Shi; Axel Rominger; Michael Hentschel
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 10.057

4.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Authors:  Ronald Boellaard; Roberto Delgado-Bolton; Wim J G Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J Verzijlbergen; Sally F Barrington; Lucy C Pike; Wolfgang A Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J Donohoe; Scott Holbrook; Michael M Graham; Giorgio Testanera; Otto S Hoekstra; Josee Zijlstra; Eric Visser; Corneline J Hoekstra; Jan Pruim; Antoon Willemsen; Bertjan Arends; Jörg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-02       Impact factor: 9.236

5.  Feasibility of PET/CT system performance harmonisation for quantitative multicentre 89Zr studies.

Authors:  Andres Kaalep; Marc Huisman; Terez Sera; Danielle Vugts; Ronald Boellaard
Journal:  EJNMMI Phys       Date:  2018-11-21

6.  89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.

Authors:  Frederike Bensch; A H Brouwers; M N Lub-de Hooge; J R de Jong; B van der Vegt; S Sleijfer; E G E de Vries; C P Schröder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

Review 7.  Long axial field of view PET scanners: a road map to implementation and new possibilities.

Authors:  Riemer H J A Slart; Charalampos Tsoumpas; Andor W J M Glaudemans; Walter Noordzij; Antoon T M Willemsen; Ronald J H Borra; Rudi A J O Dierckx; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-16       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.